Human SLC34A2 ROS1 (D2113N) BAF3 Cell Line

Description

Human SLC34A2_ROS1 (D2113N) BAF3 Cell Line is a genetically modified murine Ba/F3 model engineered to stably express the SLC34A2-ROS1 fusion containing the D2113N mutation. Lentiviral transduction was performed using AcceGen’s optimized protocol, and low passage cells (<P20) were validated for target gene expression via qRT-PCR. Target The SLC34A2-ROS1 fusion, particularly with activating mutations like D2113N, is implicated in the oncogenic transformation of lung adenocarcinoma. ROS1 is a receptor tyrosine kinase that, when aberrantly activated, drives MAPK, JAK-STAT, and PI3K pathways. Mutations such as D2113N may affect drug sensitivity and downstream signaling fidelity. AcceGen offers generation of stable overexpression cell lines targeting any gene of your interest. Polyclonal or monoclonal is optional based on customers' research needs.